Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Acerta Pharma B V is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units. This one-to-one relationship between actions, examiners, and art units indicates a diversified prosecution landscape for the company. Each pending matter is being evaluated by a different individual in a different administrative section of the USPTO, which may lead to varying prosecution timelines and outcomes.
The busiest examiner for this portfolio is SHAMEEM, GOLAM M, who is responsible for 1 busiest examiner pending office action. Given that there are 3 pending office actions and 3 distinct examiners, every examiner involved currently holds exactly 1 busiest examiner pending office action. This distribution means that no single examiner has a dominant influence over the company's pending portfolio. For a practitioner, the presence of 3 distinct art units suggests that the underlying technology for these 3 pending office actions is sufficiently diverse to require specialized review from multiple USPTO divisions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHAMEEM, GOLAM M | 1 | 86.7% | +16.0% |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746769 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18488682 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746769 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | SHAMEEM, GOLAM M | — |
| 18488682 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1622 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18746769 | Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate | SHAMEEM, GOLAM M | 1629 | §112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18613180 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | CHAO, ALLEN | 1622 | §112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18488682 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | LEE, WILLIAM Y | 1623 | §102§103§112 | Non-Final OA | — | Pending | Oct 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial